Clinical trials: Triple-negative Metastatic Breast Cancer
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
This early phase I trial studies the side effects and feasibility of cryoablation, atezolizumab, and nab-paclitaxel in treating patients with triple negative breast cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04249167
- Testing
- Atezolizumab, Cryosurgery, Nab-paclitaxel
- Sponsor
- Mayo Clinic
Estrogen Receptor Negative, Estrogen Receptor Positive
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
This phase I trial studies the side effects and the best dose of viral therapy in treating patients with squamous cell carcinoma of the head and neck that has returned (come back) after a period of improvement or has spread to…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative
- Trial name
- NCT01846091
- Testing
- Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Metastatic Triple-Negative Breast Carcinoma
Expanded Access for IMMU-132
This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.
- Trial name
- NCT04320693
- Testing
- IMMU-132
- Sponsor
- Gilead Sciences
Neoplasms, Triple-Negative Breast Cancer
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02078752
- Testing
- PF-06647263
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
This phase I/II trial study evaluates the tolerability and best tolerated dose of the PI3K inhibitor GDC-0941 when given with the chemotherapy cisplatin.
- Conditions
- Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01918306
- Testing
- cisplatin, laboratory biomarker analysis, pharmacological study
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Triple-Negative Breast Cancer
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer…
- Trial name
- NCT06382142
- Testing
- BL-B01D1, Eribulin, Vinorelbine
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Breast Cancer, Solid Tumors
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
This is a phase Ib study designed to evaluate the safety and toxicity of the combination of Alisertib and MLN0128 in patients with advanced solid tumors with an expansion cohort in patients with previously treated metastatic TNBC.
- Trial name
- NCT02719691
- Testing
- Alisertib, MLN0128
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study of IOV-5001 in Adults With Advanced Solid Tumors
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
- Trial name
- NCT07743723
- Testing
- IOV-5001
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
A Study of LY4175408 in Participants With Advanced Cancer
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
- Trial name
- NCT07046923
- Testing
- LY4175408, Pembrolizumab, Carboplatin
- Where
- 27 sites in United States, China and 4 more
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
Breast Cancer Stage IV, Triple -Negative Breast Cancer
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall…
- Trial name
- NCT06889688
- Testing
- Camrelizumab+Apatinib+Eribulin, Physician's choice chemotherapy
- Where
- 7 sites in China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01031446
- Testing
- cisplatin, everolimus, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Solid Tumor, Advanced Cancer
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary…
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05076760
- Testing
- MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memgen, Inc.
Metastatic Triple Negative Breast Cancer
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
The study hypothesise that the combination of carboplatin, gemcitabine, bevacizumab and atezolizumab may be synergistic and improve outcomes for patients with early relapsed TNBC by overcoming mechanisms of immune resistance and…
- Trial name
- BELLA (NCT04739670)
- Testing
- Atezolizumab, Bevacizumab, Gemcitabine
- Where
- 4 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Triple Negative Breast Cancer, Breast Cancer
ImmunoBreast - A Phase Ib Study
A phase Ib study to investigate the safety, tolerability and trends of efficacy of ALECSAT treatment as an add-on therapy to carboplatin and gemcitabine in patients with locally advanced or metastatic triple-negative breast…
- Conditions
- Triple Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT04609215
- Testing
- ALECSAT
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Henrik Ditzel
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body
This study will be an open-label, fixed sequence study in healthy subjects (vasectomized males and females of non-childbearing potential), performed at a single study centre.
- Trial name
- NCT04712396
- Testing
- Capivasertib, Itraconazole
- Where
- Germany
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Advanced Metastatic Triple-negative Breast Cancer (mTNBC)
A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and…
- Trial name
- NCT07340424
- Testing
- 225Ac-TR2205 Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Xiaorong Sun
Metastatic Breast Cancer, Triple Negative Breast Cancer
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
This is a Phase I study to test the safety of a combination of ASTX727 with talazoparib in patients with triple negative breast cancer or hormone resistant/HER2-negative metastatic breast cancer
- Conditions
- Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
- Trial name
- NCT04134884
- Testing
- Talazoparib, ASTX727
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Kathy Miller
Triple Negative Breast Cancer
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
This phase II trial studies how well Akt/ERK inhibitor ONC201 (ONC201) with a methionine-restricted (MR) diet works in treating participants with triple negative breast cancer that has spread to other places in the body or cannot…
- Trial name
- NCT03733119
- Testing
- Akt/ERK Inhibitor ONC201, Methionine-Restricted Diet
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Breast Cancer, Locally Advanced Breast Cancer
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
- Trial name
- NCT04699630
- Testing
- U3-1402
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- SCRI Development Innovations, LLC